Eight chronic schizophrenic inpatients received adjunctive fluoxetine
(20 mg/day) for a mean of 10.6 weeks in an open clinical trial. Clinical
state improved in all patients. Violent incidents decreased, while
participation in programs and socialization increased.Abstract Teaser